Yang W, Dong X, Li Q, Cheng Z, et al. Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial. Diabetes Obes Metab 2022 Apr 19. doi: 10.1111/dom.14722.
PMID: 35441412